This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bradley, S. V. Articles by Ross, T. S. Search for Related Content PubMed PubMed Citation Articles by Bradley, S. V. Articles by Ross, T. S.

Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies

Departments of ¹ Internal Medicine and ² Pathology, University of Michigan Medical School, Ann Arbor, Michigan and ³ Fox Chase Cancer Center, Philadelphia, Pennsylvania

Requests for reprints: Theodora S. Ross, University of Michigan, 6322 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0942. Phone: 734-615-5509; Fax: 734-647-9271; E-mail: tsross{at}umich.edu.

Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non–Hodgkin's and Hodgkin's lymphomas and that patients with lymphoid malignancies frequently had anti-HIP1 antibodies in their serum. Moreover, p53-deficient mice with B-cell lymphomas were 13 times more likely to have anti-HIP1 antibodies in their serum than control mice. Furthermore, transgenic overexpression of HIP1 was associated with the development of lymphoid neoplasms. The HIP1 protein was induced by activation of the nuclear factor-B pathway, which is frequently activated in lymphoid malignancies. These data identify HIP1 as a new marker of lymphoid malignancies that contributes to the transformation of lymphoid cells in vivo. [Cancer Res 2007;67(18):8923–31]